HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Podoplanin lymphatic density and invasion correlate with adverse clinicopathologic and biological factors and survival in neuroblastomas.

Abstract
Neuroblastoma (NB) is a challenging problem in oncology, as the majority of patients have lymphatic and/or hematogenous metastases at diagnosis. We investigated the prognostic significance of lymphatic density (LD) and invasion (LI) in NBs using the lymphatic endothelial marker podoplanin (PDPN). A total of 77 neuroblastic tumors and 9 ganglioneuromas (GNs) were immunostained for PDPN using D2-40 antibody. Intratumoral lymphatics were identified in 87% (67/77) of NBs and 7/9 GNs. The LD counts were significantly higher (P<0.01) in NBs (median=19.6, range=0.00 to 89.3) than in GNs (median=10.2, range=0 to 18.7). LI, assessed in D2-40-stained lymphatics, was present in 52/67 (78%) NBs. LDs were significantly higher in NBs from patients with adverse clinical factors (advanced-stage, high-risk group, primary abdominal compared with extra-abdominal sites), biological factors (MYCN amplification, 1p deletion, 17q gain), and distant lymph node metastases. LDs and LI were also significantly higher in NBs belonging to an unfavorable pathology prognostic group and in those with a high mitosis-karyorrhexis index. High LD and the presence of LI correlated with a shorter event-free survival in univariable analyses. High LD and the presence of LI were also associated with worse overall survival, although the association was less strong. In conclusion, increased LDs and the presence of LI correlated with adverse clinicopathologic and biological factors and survival. These findings suggest that PDPN has the potential to provide valuable prognostic information to clinicians for risk assessment in NBs.
AuthorsPramila Ramani, Michelle S Somerville, Margaret T May
JournalThe American journal of surgical pathology (Am J Surg Pathol) Vol. 36 Issue 6 Pg. 908-15 (Jun 2012) ISSN: 1532-0979 [Electronic] United States
PMID22588067 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers, Tumor
  • MYCN protein, human
  • Membrane Glycoproteins
  • N-Myc Proto-Oncogene Protein
  • Nuclear Proteins
  • Oncogene Proteins
  • PDPN protein, human
Topics
  • Abdominal Neoplasms (genetics, metabolism, mortality, pathology)
  • Biomarkers, Tumor (genetics, metabolism)
  • Child
  • Child, Preschool
  • Ganglioneuroma (genetics, metabolism, mortality, pathology)
  • Gene Amplification
  • Humans
  • Infant
  • Infant, Newborn
  • Lymphatic Metastasis
  • Lymphatic Vessels (metabolism, pathology)
  • Membrane Glycoproteins
  • N-Myc Proto-Oncogene Protein
  • Neoplasm Invasiveness
  • Neuroblastoma (genetics, metabolism, mortality, secondary)
  • Nuclear Proteins (genetics)
  • Oncogene Proteins (genetics)
  • Prognosis
  • Survival Rate
  • United Kingdom (epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: